Your AI-Trained Oncology Knowledge Connection!
Panelists discuss how effective patient education, coordinated multidisciplinary care, strong caregiver advocacy, and proactive management of talquetamab’s unique adverse effects through standardized protocols and comprehensive handouts enable patients with relapsed/refractory multiple myeloma to successfully navigate bispecific antibody therapy while maintaining quality of life.
Binod Dhakal, MD, MS, and Karen Kehl discuss how bispecific antibody therapy with talquetamab has transformed the treatment journey for a multiple myeloma patient who achieved durable responses after 19-plus prior treatments, exploring the drug's mechanism targeting GPRC5D, clinical trial data showing 70% response rates, practical considerations including step-up dosing strategies and manageable adverse effects like taste changes and nail issues, and the patient's positive quality of life outcomes that have allowed her to continue living actively 16 years post diagnosis.
Leyla O. Shune, MD; Mindy Kupchin, RN; and Tina Kellogg discuss how chimeric antigen receptor (CAR) T-cell therapy has emerged as a superior second-line treatment for relapsed/refractory multiple myeloma (MM), sharing clinical insights on the CARTITUDE-4 trial results, patient experience with ciltacabtagene autoleucel, and the multidisciplinary care coordination required to successfully deliver this immunotherapy that offers patients deeper remissions, improved quality of life, and potentially prolonged survival compared with standard chemotherapy approaches.
Panelists discuss how a multidisciplinary, patient-centered approach, including shared decision-making and the integration of immunotherapy and targeted therapies, is essential for optimizing the treatment and management of advanced renal cell carcinoma (RCC).
Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy is transforming the treatment of relapsed/refractory multiple myeloma, highlighting the decision-making process, patient preparation, management of adverse effects, and the importance of multidisciplinary collaboration to optimize outcomes and improve quality of life.
Panelists discuss how multiple myeloma patients and healthcare providers navigate the comprehensive CAR-T therapy journey, from initial diagnosis through treatment selection, therapy administration, and long-term follow-up care, while sharing clinical insights and personal experiences about treatment outcomes, side effect management, and quality of life improvements.
Panelists discuss how a multidisciplinary approach and shared decision-making are crucial in managing advanced HER2+ breast cancer, emphasizing the integration of expert insights with patient experiences for optimal treatment outcomes.
Thomas Hutson, DO, PharmD, leads a discussion with his patient, Mr. Cesar Fuentes, and colleague Kacie Ellis, RN, focusing on the evolving treatment practices in advanced renal cell carcinoma and sharing patient and clinician perspectives.
Moderator Rohit Jain, MD, MPH leads a discussion with Anand Shah, PharmD, BCOP, Mr. Jeffery Ehas, and Mrs. Lauren Ehas, focusing on the evolving treatment practices in bladder cancer. Panelists assess the latest data, evaluate the impact on treatment decisions, and share patient and caregiver perspectives.
A panel of healthcare professionals, joined by a patient and her caregiver, discuss the diagnosis of renal cell carcinoma, available treatment options, and patient education strategies.
